Stay updated with breaking news from Support Accelerated Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On April 6, 2023, AbbVie announced that it was voluntarily withdrawing ibrutinib, which was granted accelerated approval for two indications: mantle...
On April 6, 2023, AbbVie announced that it was voluntarily withdrawing ibrutinib, which was granted accelerated approval for two indications: mantle...
/PRNewswire/ -- Today, the U.S. Food and Drug Administration issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology...
One-Stop Business and Finance News